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RESUMO
Introdução: Todos os medicamentos de uso humano são comercializados com um folheto informativo. Estes documentos devem ter 
uma lista inicial com a identificação de todas as secções, de acordo com o modelo europeu Quality Review of Documents e não serem 
muito extensos, i.e. com cerca de 1500 palavras. Apenas excepcionalmente são autorizados folhetos relativos a mais de uma dose e/
ou forma farmacêutica (folhetos mistos). Neste contexto, os objectivos incluem a identificação de problemas nos folhetos informativos 
de todos os medicamentos não genéricos portugueses quanto à presença da lista inicial, à frequência de folhetos mistos e ao número 
de páginas. 
Material e Métodos: Consulta dos folhetos na base pública Infomed de acordo com a classificação do Prontuário Terapêutico – 10 (1º 
trimestre 2012). Os dados recolhidos foram sujeitos a controlo de qualidade e tratamento estatístico. 
Resultados: Identificação de 2729 folhetos em 3080 especialidades farmacêuticas. Foram avaliados 2042 folhetos (687 não estavam 
disponíveis), em que 181 (8,9%) não apresentaram lista inicial e 351 (17,2%) eram mistos. O número médio de páginas foi 6,9 (DP = 
2,6), o mínimo = 2 e o máximo = 26.
Discussão: A leitura e compreensão adequadas dos folhetos portugueses em alguns casos podem estar comprometidas, dado que 1) 
alguns dos folhetos analisados não continham a lista inicial necessária à adequada localização das informações, 2) foram detetados 
folhetos mistos e/ou 3) foram encontrados folhetos com uma extensão acima do desejável. 
Conclusão: Os resultados deste estudo devem informar o processo de desenvolvimento e aprovação dos folhetos pelos titulares da 
autorização da introdução no mercado e pelas autoridades reguladoras. 
Palavras-chave: Folhetos Informativos; Rotulagem de Medicamentos; Portugal.
ABSTRACT
Introduction: All medicines for human use are marketed with a package leaflet. Every package leaflet must contain an initial list men-
tioning all sections of the document in accordance to the European template Quality Review of Documents, being not to extensive, i.e. 
comprising approximately 1500 words. The so-called mixed leaflets contain information about medicines with more than one strength/
pharmaceutical form, and only exceptionally are authorized. In this context, the objectives of the present study comprised the identifica-
tion of issues in all package leaflets of Portuguese non-generic medicines: 1. to confirm the presence of an initial list, 2. to quantify the 
number of mixed leaflets, and 3. to evaluate their length (in number of pages). 
Material and Methods: Consultation of the leaflets, in a public database (Infomed), according to the classification of the National Pre-
scribing Guide (1st trimester 2012). The data collected was subject to quality control and statistical analysis. 
Results: Identification of 2729 package leaflets, representing 3080 medicines. A total of 2042 leaflets were evaluated, with 181 (8.9%) 
missing the initial list and 351 (17.2%) being mixed. The average number of pages was 6.9 (SD=2.6), the minimum = 2 and the maxi-
mum = 26. 
Discussion: In some cases, readability and comprehension of some Portuguese leaflets might be compromised since: 1) some leaflets 
did not contain an initial list, 2) were classified as mixed leaflets, and/or 3) were classified as too extensive. 
Conclusion: Regulatory authorities and marketing authorization holders might need to take into consideration these issues during the 
development and approval of package leaflets.
Keywords: Pamphlets; Drug Labeling; Portugal.
INTRODUCTION
 The inclusion of a package leaflet in the packaging of all 
medicinal products is obligatory in the European Union, un-
less all the required information is directly conveyed on the 
outer packaging (article 58 of the Directive 2001/83/EC).1 
The patient information leaflet (PIL) should be designed ac-
cording to the information included in the Summary of Prod-
uct Characteristics (SPC), a document containing informa-
tion aimed at health professionals (article 59 of the Directive 
2001/83/EC, transposed at national level to Decree-Law nº 
176/2006 (article 106).2
 Package leaflets of medicinal products must comply with 
certain characteristics, such as: 1) ease of understanding, 
facilitating localization of drug characteristics and 
understanding of its content, 2) efficiency, allowing for quick 
and successful consultation and 3) usefulness for the lay 
users.3 In addition to clarity and simplicity, its readability 
is also related to graphic and typographic aspects of the 
text, such as organization of headings and document 
navigability.4,5
 The structure of package leaflets is defined according to 
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the QRD - Quality Review of Documents European model6 
and with the exception of QRD’s versions 1 and 2 (from 
1996/97), every subsequent version includes an initial 
table of contents of all the main sections of the document. 
According to QRD’s last version (nº 9, 2013), this table must 
comply with the following:
 1. What X is and what it is used for;
 2. What the patient should know before <taking it> <use 
it>;
 3. How to <take it> <use it>;
 4. Possible side effects;
 5. Storage conditions;
 6. Package contents and further information.6,7 
 The table of contents is particularly useful for the patient, 
as it is known that package leaflets are often selectively 
read by patients, i.e. patients only look for information 
regarding a certain issue (such as dosage).8 The so-called 
combined or mixed package leaflets, regarding more than 
one pharmaceutical strength or form, are only allowed 
in exceptional or duly justified cases, in order to ensure 
the leaflet´s simplicity. In these, clarity and simplicity of 
information regarding dosage and method of administration 
is crucial.9 
 According to the results of a cross-over study carried out 
in Jena’s region (Germany) involving 1,105 participants in 
a  1st and 1,057 in a second phase project, questionnaires 
were applied to evaluate the perception of the information 
included in original as well as in modified or simplified 
package leaflets for five different drugs (enalapril, 
ibuprofen, paracetamol, repaglinide and telmisartan). 
The following requirements were considered in order to 
change the leaflets: 1) presentation of the information 
in a more concise format, 2) preferred font size: 11 pt, 3) 
contrasting background colours, 4) utilization of coloured 
titles in bold, 5) dosage expression as number of tablets 
or as exact volume, 6) avoidance of foreign words, 7) 
shorter sentences, 8) reducing expressions non-related to 
an exact quantification (as in “high dosages”), 9) avoiding 
abbreviations and repetitions. We obtained 92.6-94.4% 
correct responses with the modified/simplified version in 
comparison to only 74.7-85.8% with the original package 
leaflets. The dosage presentation was among the major 
issues identified in the original texts, which should be short 
and precise, preferably with the administration instructions 
quantified in terms of number of units or volume.10 Another 
study involving 452 participants attending 17 German 
community pharmacies found that 192 (42.5%) participants 
referred to difficulties in reading the package leaflets and 96 
(21.3%) referred to some difficulties in understanding drug 
dosage.11 Another survey on package leaflets, carried out 
in Germany and involving 1,900 people, found that most 
responders 1) read the documents, 2) ranked these as 
lengthy, 3) considered the information as unhelpful (one in 
five qualified it as unintelligible), and 4) 28% had already 
stopped taking the medication on at least one occasion due 
to misunderstanding of the content of the package leaflet.12
 Lengthy package leaflets are known to add a layer of 
difficulty to patient understanding.12-16 Research involving 
271 package leaflets of medicines available to the German 
market found that the information provided by more recently 
approved leaflets increased in terms of the amount of text, 
particularly regarding technical information.13 The tendency 
towards increasing the content in package leaflets was 
also confirmed in a review study on the changes over time 
regarding the QRD model.6 A controlled study involving 
192 participants compared 3 package leaflets organized 
according to the German version of the QRD model (normal 
version) vs. the reduced/simplified version, i.e. specifically 
developed for the study. A questionnaire was applied in 
order to assess package leaflet’s understanding and the 
shorter models were shown to be more adequate, with a 
better understanding in 15.7% of the cases and a 18.1% 
(p<0.05) reduction in the time taken to locate the information 
in the text.14 
 Our study aimed to identify and confirm the presence of 
a table of contents, to quantify the mixed package leaflets 
likely to contain more complex dosage information and to 
assess the amount of text in leaflets (in number of pages), 
considering as relevant the potential impact of some of the 
general information in the leaflet on the adequate use of non-
generic Portuguese drugs. In addition, the amount of text 
in lengthier leaflets assessed in this study was compared 
to the amount of text in at least one leaflet of a drug with 
the same formulation and pharmaceutical form, approved 
by a non-European Agency, also available for consultation 
in a public database and in which the same aspects were 
included. 
MATERIAL AND METHODS
 Our study followed a descriptive and cross-over design, 
carried out on the first trimester of 2012, based on the 
leaflets that were published in the Infomed database.17 A 
search for different non-generic drugs was carried out in this 
database, according to the classification of the Portuguese 
prescribing compendium (Prontuário Terapêutico – 10).18 
Infomed is a public open-access database managed by the 
Portuguese medicines authority (INFARMED – Autoridade 
Nacional do Medicamento e Produtos de Saúde, I.P.) 
and includes information on all medicinal products in the 
Portuguese market, namely their package leaflets. 
 The leaflets regarding hospital medicinal products 
were excluded from the study as most of these are to 
be administered under a health’s professional direct 
intervention. Our study did not assess any leaflet regarding 
medicinal products ranked as generic, as these have a 
similar structure as non-generic medicines. In addition 
our study did not concern  any case when an arbitration 
procedure regarding the reference medicine was expected 
to be in accordance with article 30 (2) of the Directive 
2001/83/EC1, upon which the harmonised text regarding the 
summary of product’s characteristics and package leaflet 
will be published. All leaflets regarding drugs classified 
as generic or as exclusive for hospital administration, in 
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accordance with the classification system of this database 
(including branded generic medicines), were excluded from 
the study.
 All leaflets regarding non-generic medicines identified 
in the Infomed database were characterised according to 
the following variables: presence of a table of contents (vs. 
absence), mixed (combined) package leaflets (vs. single) 
and number of pages per leaflet, according to the layout of 
the documents published in the database. In addition, they 
were classified according to a group of variables associated 
to the available classification in the Infomed database and 
in the Prontuário Terapêutico – 10:18 chemical composition, 
therapeutic group, medicine status (prescription-only [POM] 
vs. over-the-counter [OTC] medicines), type of approval 
(with vs. without centralised European Medicines Agency – 
EMA approval) and route of administration (oral, parenteral 
or dermal,). Although the centrally approved leaflets are not 
directly accessible in the Infomed database, this provides 
a link to EMA’s site, where these leaflets are available for 
public online access.
 All the variables were organized into a Microsoft Excel 
file and subject to quality control using the principles 
established in the NBR 5425 regulatory standard19 with 
randomization and re-analysis of approximately 10% of 
the identified leaflets. According to the quality control 
methodological principles no errors were detected. These 
pre-defined principles establish that the identification of 
more than one error by variable would involve re-assessing 
all the identified leaflets, as well as a second analysis, which 
proved unnecessary in our study.
 At the same time, the number of words in the lengthier 
leaflets (herewith described as outliers or leaflets containing 
a number of pages considered as excessive when exceeding 
three times the interquartile range) were compared to the 
number of pages and words in at least one leaflet associated 
to a drug with similar pharmaceutical composition and 
form, available in the Australian public medicines agency 
(Therapeutic Goods Administration – TGA).20 The number of 
words was quantified using the MS Word software, with the 
Word Count tool. The comparison of the number of words 
(instead of the number of pages) allows for a more precise 
analysis, especially due to the fact that the Australian 
package leaflets are published in three-column formatted 
documents, making a direct comparison more difficult. The 
leaflets in this database were selected as comparators as 
they are available online (unlike in the United States, where 
not every medicine has its leaflet available)21 and because 
they are approved by an extra-European medicine agency, 
i.e. following regulation principles not exactly overlapping 
but still similar to the European package leaflets.20 
 The SPSS for Windows (version 19.0, IBM-SPSS, 
Chicago, IL) software was used for statistical analysis, 
involving the determination of the parameters of descriptive 
statistics as well as the statistical differences between 
groups of leaflets ranked by pages (2 to 5, 6 to 10 and 
more than 10 pages), with a p < 0.05 significance level. The 
intervals regarding the number of pages were based on the 
analysis of the distribution of their frequencies.
RESULTS
Identified, selected and excluded leaflets
 From a total of 2,729 (100%) package leaflets associated 
to non-generic medicines and covering 3,080 medicinal 
products, 2,042 (74.8%) were selected for evaluation, as 
687 (25.2%) were not available in the Infomed database.17 
None of these 687 leaflets is associated to any of the 
Portuguese top-seller 100 International Non-proprietary 
Names22 or to any centrally approved medicine. A total of 
115 leaflets associated to hospital medicines were excluded 
from the study.
Leaflets with (vs. without) initial table of contents
 As regards the 2,042 evaluated leaflets, 181 (8.9%) 
did not include a table of contents. We should mention that 
no centrally approved leaflet was found without a table of 
contents.
 The distribution of leaflets with initial table of contents 
(1,861) by the different medicinal products is shown in Table 
1. The medicines described in these leaflets were mainly 
given orally, parenterally or directly to the skin (dermal route) 
(59.2%, 15.8% and 11.1% from 1,861 leaflets, respectively).
 The leaflets without table of contents regarded mostly 
medicines used in pathologies of 1) central nervous 
system, 22%, 2) gastrointestinal system, 19.9% and 3) 
musculoskeletal system, 15.5% (40, 36 and 28 from 181 
leaflets, respectively). 
Mixed (combined) leaflets
 In total, 354 (100%) mixed leaflets were identified, from 
which 351 (99.1%) included an initial table of contents 
and 3 (0.1%) did not. The distribution of the mixed leaflets 
according to the medicine’s status and the type of approval 
is shown in Table 2.
 In the mixed leaflets with table of contents, 1) angiotensin-
converting enzyme inhibitors, 7.4%, 2) antidepressants, 
7.1%, and 3) antipsychotic, 4.8% (26, 25 and 17 from 351 
leaflets, respectively) were the medicinal product groups 
most frequently found.
Leaflet’s amount of text
 As regards the distribution of the number of pages on 
the leaflets with vs. without initial table of contents regarding 
prescription-only vs. OTC medicines, with centralised 
approval or any other type of approval, the descriptive 
statistics parameters and statistical differences are shown 
in Table 3. According to the p-values shown in this Table, 
a higher percentage of lengthier leaflets were found, 
statistically significant in the group of leaflets with initial 
table of contents regarding prescription-only or centralised 
approved medicines.
 In addition to the data shown in Table 3, we found that 
in the case of leaflets associated to POM, 75.5% (278 in 
368) had less than 6 pages, while 63.6% of the leaflets 
associated to OTC medicines (950 from 1,493) had 6 to 
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10 pages. We found some medicine’s leaflets with more 
than 10 pages: 0.8% associated to POM and 10.8% to OTC 
medicines.
 Hormones and drugs used in treatment of endocrine 
pathology were those with lengthier leaflets (average = 9.5 
pages; SD = 3.2) together with immune modulator drugs 
and antineoplastic drugs (average = 8.5 pages; SD = 3.1). 
The medicinal products group used in dermal pathology 
had the shortest leaflets (average = 4.6; SD = 1.5).
Comparison with leaflets from abroad
 Shorter leaflets than Portuguese leaflets ranked 
as extreme outliers were found in the Australian TGA 
database20, within the group of selected leaflets used for 
the comparative study (Table 4).
DISCUSSION
Assessed leaflets
 Our sample of 2,042 leaflets was considered as 
appropriate to our study as the leaflets of every non-generic 
drug described in the Prontuário Terapêutico – 1018 was 
identified at the Infomed database,17 even considering that 
some of these were not available in this database. 
Leaflets with vs. without initial table of contents
 The fact that some leaflets with no initial table of contents 
exist, i.e. without an initial description of every chapter on 
the leaflet, suggests that there are still leaflets designed 
according to expired QRD models in the public database, 
although the presentation of such a table was recommended 
from the third version of the QRD model onwards (1998).6 It 
may prove to be more difficult for the patients to locate the 
information in these leaflets therefore inducing less efficient 
reading. Considering that the patients often only look for 
specific information on the package leaflets, such as 
those regarding dosage or adverse reactions,23 the lack of 
navigability of the documents may affect an efficient search 
for the required information.
Table 1 - Distribution of package leaflets by the different therapeutic groups
Therapeutic Group in the Portuguese 
Prescribing Guide
Available leaflets*
(n)
Available leaflets†
(%)
Unavailable leaflets†
(%)
G1: Infections 163 74.4 25.6
G2: Central Nervous System 309 73.0 27.0
G3: Cardiovascular System 179 80.6 19.4
G4: Blood 59 66.3 33.7
G5: Respiratory System 123 76.9 23.1
G6: Gastrointestinal System 176 61.5 38.5
G7: Genito-urinary System 69 81.2 18.8
G8: Hormones  167 85.2 14.8
G9: Musculoskeletal System 162 87.1 12.9
G10: Allergy 39 92.9   7.1
G11: Nutrition 30 47.6 52.4
G12: Volume replacement  26 36.1 63.9
G13: Skin disorders 143 58.1 41.9
G14: E&T disorders  25 80.6 19.4
G15: Eye disorders  87 80.6 19.4
G16: Oncology 65 85.5 14.5
G17: Poisoning 1 33.3 66.7
G18: Vaccines  37 92.5   7.5
G19: Diagnostics 1 100.0   0.0
Total 1861
n: number of leaflets.
 * Number of available leaflets with table of contents; † % of available vs. unavailable leaflets in the Infomed public database.16
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Mixed (combined) leaflets
 The mixed leaflets identified in our study concern the 
description of information on medicines with more than a 
single dosage or pharmaceutical form in the same leaflet.9 
Among other issues, the information regarding dosage or 
administration form should be more difficult to look for due 
to the presence of competing facts. In  these cases, the 
reader has to distinguish the different information available 
on the leaflet i.e. the reader has to specifically identify the 
dosage and/or the pharmaceutical form that best apply to 
his treatment.
 We should mention that although dosage is a particularly 
important aspect for an adequate drug administration and 
is considered by patients as a major item,24 the issues 
regarding an adequate presentation are not uncommon.10,11 
Furthermore, the higher percentage of mixed leaflets is 
found in the top-selling group of medicinal products, such 
as  leaflets regarding drugs used in the central nervous 
system and the musculoskeletal system,22 suggesting an 
intense use and reading of mixed leaflets.
 Unlike what would be expected, the national regulation25 
does not include any additional recommendation regarding 
the approval of mixed leaflets,9 although the EMA guidelines 
are followed in Portugal, as in the remaining countries of the 
European Union. Apparently, the EMA uses more selective 
mechanisms for the approval of mixed leaflets, considering 
that a much lower percentage of this type of leaflets has 
been detected in medicines with centralised approval.
Amount of text in leaflets
 Some lengthy leaflets were found (outliers). This does 
not improve reading and understanding of leaflets by 
patients, according to different studies6,12-16. 
 In addition, it has been estimated that the leaflets 
Table 2 - Distribution of mixed (combined) leaflets
Total
(n)*
Total
(%)
Non-Mixed
(n)
Mixed
(n) Ratio
†
Medicine’s status
   POM 1493 80.2 1166 327 3.6
   OTC 368 19.8 344 24 14.3
   Total 1861 100 1510 351
Type of approval
   Centralised 178 9.6 158 20 7.9
   Other 1683 90.4 1352 331 4.1
   Total 1861 100 1510 351  
n: number of leaflets with table of contents; POM: prescription-only medicines; OTC: over-the-counter medicines. 
* Total = Mixed + Non-mixed; † Number of non-mixed leaflets divided by the number of mixed leaflets. 
Table 3 - Distribution of the number of pages in leaflets
Number of pages
Total (n) % Average Standard 
deviation
Minimum Maximum
Pearson 
Chi-square
p
Table of contents
  Without 181 8.9 4.9 2 2 15
60.6 < 0.001
  With 1861 91.1 6.9 2 2 26
  Total 2042 100
Medicine’s status
  POM 1493 80.2 7.3 2.6 2 26
325.4 < 0.001
  OTC 368 19.8 4.9 1.5 3 12
  Total 1861 100
Type of approval
  Centralised 178 9.6 8.3 2.6 4 17
67.3 < 0.001
  Other 1683 90.4 6.7 2.6 2 26
  Total 1861 100
n: number of leaflets; POM: prescription-only medicines; OTC: over-the-counter medicines.
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included in our study contained on average approximately 
2,800 words, considering that 1) the average number of 
pages of the assessed leaflets was approximately seven 
and two) one standard A4 sheet written in serifed font size-
11 includes about 400 words. The estimated value of the 
number of words is questionable as the documents available 
in the Infomed database are not exactly homogeneous 
regarding format, i.e. they show slight variations in 
sizes, fonts, margins and line spacing (non-standardized 
documents). According to another study by the authors, 
in a sub-sample of 531 randomized leaflets from all the 
leaflets selected to the present study 1) there was a 1,860 
word average (± 860), 2) 195 leaflets (37%) included more 
than 2,000 words and 3) 105 (20%) leaflets had more than 
2,500 words.
 As such, the authors quantified the number of words in 
a small set of leaflets associated to centralised approved 
medicines in the German and in the Portuguese markets 
and published in EMA’s site, in order to build an indicator 
regarding the variations in the number of words due to 
differences in language. This assessment confirmed that 
the Portuguese and German leaflets had a similar number 
of words, with only just 5% more words in the case of 
Portuguese leaflets, i.e. even considering the variations 
due to the language, some of the Portuguese leaflets are 
apparently too lengthy.
 We should mention that the level of education may have 
a strong impact on the way patients from each country use 
leaflets. In the case of the Portuguese population, it is known 
that 44% has basic schooling levels, a higher percentage 
than in German population (3% of the population).26 
Therefore, it would be expected that lengthy leaflets have 
an even stronger impact on understanding and adequate 
use in the Portuguese population. In contrast, we also 
should mention that, although shorter leaflet production is 
recommended, i.e. with less than 1,500 words,15  it cannot 
be expected that all the leaflets would have this amount of 
text, as this rather depends on the relevant information for 
each medicine and substance.
 Shorter leaflets without initial table of contents may be 
explained by their structure having been built according 
to older and shorter QRD models,6 i.e. applied to the 
insertion of less information, when compared to more 
recent QRD models.6,7 In addition, the fact that OTC leaflets 
are significantly lengthier than those regarding POM may 
be explained by the higher technical complexity of the 
information that is needed to be included in POM’s leaflets.25 
The fact that leaflets regarding centralised approved 
medicines are significantly shorter when compared to 
those without this type of approval may be also explained 
by the higher technical complexity of the information that is 
needed to be included in these medicines, such as with the 
new antineoplastic agents or the new drugs for diabetes.2 
Comparison to leaflets in other countries
 Leaflets regarding medicines with the same composition 
and pharmaceutical form were found in the TGA database20 
with approximately half of the words of leaflets ranked 
as extreme outliers. This reinforces the view that at least 
some of the Portuguese leaflets could be shorter. Even 
considering that a shorter number of words would be 
expected (approximately 6%) in leaflets written in English, 
when compared to the Portuguese translations of the same 
leaflet (value also based in the analysis of a small sample 
of leaflets published in the EMA’s site written in English and 
compared to the version in Portuguese published in the 
same site), we think that inter-language variations do not 
explain the excessive length of leaflets ranked as extreme 
outliers.
Final considerations
 Simplicity and clarity of written information are crucial 
in order to allow for readability of medicines’ leaflets.5,27,28 
Therefore, we consider that our study assessed relevant 
parameters to ensure simplicity, clarity and efficacy of 
the information in leaflets. Considering that there are no 
other similar studies published in Portugal, our study may 
correspond to a first contribution to improve Portuguese 
leaflet readability.
 Globally, the issues found in package leaflets reinforce 
Table 4 - Comparison of the Portuguese package leaflets considered as outliers vs. leaflets approved by the Australian Agency
Number of words  *
Composition Pharmaceutical Form Portuguese Leaflet Australian Leaflet Reduction rate † Name of the Australian 
medicine
Botulinum Toxin 
type A
Powder for solution for 
injection
7263 4053 55.8% Botox
Somatropin
Powder for solution for 
injection
3710 1653 55.4% SCITROPIN A 5mg/1.5mL
Risperidone
Powder for solution for 
injection
5559 2551 45.8% Risperdal
Etonogestrel Implant 6662 4289 35.0% Implanon
Levonorgestrel Intrauterine device 4832 3331 31.0% Mirena
* The number of words was quantified according to the documents published in the websites of the Portuguese and Australian Medicines Regulation Agencies17,20
† The reduction rate was quantified according to the reduction on the number of words.
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the importance of the information given to patients by health 
professionals. In this fashion, patients have an opportunity 
to clarify their doubts and to receive information considered 
as crucial for the rational and safe use of medicines.29-31 In 
addition, research on adequacy of presentation and amount 
of text in package leaflets, as well as the assessment of 
the impact of the use of mixed (combined) leaflets in health 
outcomes, should include specific readability tests aimed to 
assess response variations between patients or potential 
drug users in the different countries of the European Union, 
as there is heterogeneity in educational levels among these 
populations.26
 Although this was not the major focus of the present 
study, we found that some leaflets were not available in 
the Infomed database, which may eventually compromise 
the immediate access to the information by users (patients 
and health professionals), even considering that the latter 
preferably read the summary of product characteristics, 
which is also published in this database. This situation may 
be explained due to temporary regular updates. However, 
we should mention that on the first trimester of 2014 an 
average number of 265,000 visits to the website of the 
INFARMED (Study Topic/Tráfego de visitas ao sítio http:\\
www.infarmed.pt. Unpublished raw data, 2014) confirms the 
importance of online information, even though the number 
of searches by health professionals only vs. other users is 
not known. There are several links in Infomed’s website to 
non-accessible leaflets. 
 As regards leaflets associated to centralised approved 
medicines, no unavailable leaflets were found, showing 
the reliable online publication of these leaflets by the EMA. 
We should also mention the fact that these leaflets are 
not directly available in Infomed’s database, i.e. there is 
a re-routing from Infomed’s website to the EMA’s website, 
consequently increasing the level of difficulty for some 
users as, despite leaflets being available in Portuguese, the 
information in the EMA’s website is written in English.
Study limitations
 Although approximately 80% of all leaflets regarding 
non-generic medicines were included in the Portuguese 
Prontuário Terapêutico – 10,18 the exact number of medicines 
absent from the list was not determined. Therefore, the 
number of non-generic medicine’s leaflets that were not 
analysed is not known. The fact that the leaflets associated 
to hospital drugs were not included in the study may also 
be considered as a limitation as although most of these 
medicines are to be administered by health professionals, 
in some cases these may also be used by patients. Finally, 
the amount of text in leaflets was assessed by the number 
of pages of the official documents published online, instead 
of the real leaflets, which does not allow for an estimation of 
the real extension of the information in the original package 
leaflets.
CONCLUSION
 Our study found that some leaflets do not include an initial 
table of contents, do not show separate sections regarding 
pharmaceutical strength or form, or are too lengthy. Reading 
and understanding of some leaflets regarding Portuguese 
medicines may be eventually compromised. The issues 
identified in this study should be taken into consideration 
in the future by marketing authorisation holders and by 
regulation authorities during the development and approval 
of leaflets associated to Portuguese medicines.
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